Evonile Pharma — 360° view

Evonile Pharma, a company in the Pharmaceuticals industry, reported revenue of ₹56 crore and a net loss of ₹78 crore for the September 2026 quarter.

Evonile Pharma (NSE: EVONILE) closed at ₹1,367.60 on 20 Nov 2026. Its market capitalisation is ₹4,784 crore and it trades at 74.4 times earnings.

Share price
₹1,367.60 (20 Nov 2026)
Market cap
₹4,784 Cr (20 Nov 2026)
P/E
74.43 (20 Nov 2026)
Revenue
₹56 Cr (September 2026 quarter)
Net profit
₹-78 Cr (September 2026 quarter)
ROCE
16.3% (FY26)
ROE
11.6% (FY26)
Book value
₹263 (FY26)
Dividend yield
0.00% (last 12 months to 20 Nov 2026)
52-week high / low
₹2,588.80 / ₹950.00 (20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: EVONILE

Novartis India Ltd is primarily engaged in the Business of Wholesale of pharmaceuticals and medical goods. It imports various medicines to India from different sources across the globe.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.